{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"7.56","value":"1.33"}]}]}],"denomUnitsSelected":"Scores","denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"194"}],"units":"Scores"}],"description":"Distress is measured on a scale of 0-10 on the National Comprehensive Cancer Network Distress Thermometer (NCCN DT). A score of 0 represents no distress, and a score of 10 represents worst possible distress. Actionable distress is defined as a NCCN DT score of 4 or higher, and is aligned with the medical practice guidelines for management of distress in cancer patients.The median (min, max) distress score across patients is reported.","dispersionType":"Full Range","groups":[{"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023","id":"OG000","title":"Multiple Myeloma/Blenrep Participants"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.","title":"Magnitude of Distress Using National Comprehensive Cancer Network Distress Thermometer (NCCN DT)","type":"SECONDARY","typeUnitsAnalyzed":"Scores","unitOfMeasure":"DT Score"}